依普利酮是哪个国家的？

Which country is it from?

Eplerenone was developed by Pfizer of the United States and was first launched in the United States in 2004. It is suitable for essential hypertension and heart failure after myocardial infarction. For severe hypertension that cannot be controlled by a combination of multiple antihypertensive drugs, the addition of eplerenone (Inspra) can significantly reduce blood pressure, especially the decrease in systolic blood pressure is more significant. The combined treatment of eplerenone, angiotensin-converting enzyme inhibitor (ACEI) and receptor blockers can improve patients' quality of life and reduce mortality in severe heart failure and myocardial infarction.

The initial dose of eplerenone (Planep) for the treatment of congestive heart failure is 25 mg, administered orally once daily; it can be increased to the target dose within four weeks as tolerated by the patient. The target dose is 50 mg orally once daily. 

  When treating adult patients with hypertension, eplerenone (Planep) can be used alone or in combination with other antihypertensive drugs. It is administered orally. The initial dose is 50 mg, once a day; the maintenance dose is 50 mg, 1-2 times a day. The maximum dose is 100 mg/day and patients should not overdose. Typically, significant blood pressure lowering effects occur within four weeks of taking eplerenone. Patients whose blood pressure responds inadequately to the initial dose may be increased to 50 mg twice daily. During the period of treatment with this drug, patients should not increase or decrease the drug without authorization. Only correct use of the drug will help the condition.

Eplerenone also has a good antihypertensive effect on simple systolic hypertension and has a good antihypertensive effect on diet-induced obesity-related hypertension. In addition, eplerenone (Planep) can significantly reduce the ultrafiltration effect of glomeruli and reduce albuminuria in patients with hypertension. This renal protective effect is more obvious for hypertensive patients with diabetes.

The above is the introduction about (eplerenone), I hope it can help everyone. If patients have other questions about the drug (such as drug price, purchasing channels, etc.), they can consult the medical companion travel service. 

Recommended related hot articles: /newsDetail/83252.html